Clinical trials: Stage IV Breast Cancer
First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
This is a randomized, controlled, open-label, multicenter, phase Ш clinical study designed to compare the efficacy and safety of KN026 in combination with HB1801 to trastuzumab in combination with pertuzumab and docetaxel in the…
- Trial name
- NCT05838066
- Testing
- Recombinant Humanized Bispecific antibody against HER2，KN026, HB1801, Pertuzumab
- Where
- China
- Volunteers
- 880 people
- Sponsor
- Shanghai JMT-Bio Inc.
Metastatic Breast Cancer
Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer
The purpose of this study is to visualize and quantify ER-binding sites during treatment with Elacestrant (RAD1901)
- Trial name
- NCT02650817
- Testing
- RAD1901
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 16 people
- Sponsor
- Stemline Therapeutics, Inc.
HR+/HER2-negative Breast Cancer
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
The goal of this clinical trial is to evaluate the safety and efficacy of TOS-358 in women with HR+ HER2- metastatic breast cancer whose tumors have a mutation in PIK3CA and who meet all other study enrollment criteria.
- Trial name
- NCT05683418
- Testing
- TOS-358, Fulvestrant, Palbociclib
- Where
- 18 sites in United States, Spain
- Volunteers
- 241 people
- Sponsor
- Totus Medicines
Breast Cancer
A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.
This single arm. open-label study will assess the efficacy and safety of Herceptin (trastuzumab) in combination with Xeloda (capecitabine) in patients with metastatic or recurrent HER2-positive breast cancer, refractory to or…
- Trial name
- NCT01290718
- Testing
- capecitabine [Xeloda], trastuzumab [Herceptin]
- Where
- 6 sites in Taiwan
- Volunteers
- 4 people
- Sponsor
- Hoffmann-La Roche
Metastatic Breast Cancer
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
The purpose of this study is to find out the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDEs) of JNJ-101684362 (HLD-0117), to evaluate the safety of JNJ-101684362 (HLD-0117) , and how well the…
- Trial name
- HLD-0117 (NCT07524855)
- Testing
- JNJ-101684362 (HLD-0117)
- Where
- 7 sites in United States, Australia
- Volunteers
- 170 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Breast Cancer
Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer
To determine the overall objective response rate of pegylated liposomal doxorubicin （Lipo-Dox）combined with cyclophosphamide/5-FU as second-line treatment in patients with metastatic breast cancer.
- Trial name
- NCT01451580
- Testing
- Lipo-Dox
- Where
- Taiwan
- Volunteers
- 47 people
- Sponsor
- TTY Biopharm
HER2+ Metastatic Breast Cancer (MBC)
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
This is a randomized, multi-center, multinational, open-label, active-controlled, parallel design study of the combination of neratinib plus capecitabine versus the combination of lapatinib plus capecitabine in HER2+ MBC patients…
- Trial name
- NALA (NCT01808573)
- Testing
- neratinib, capecitabine, lapatinib
- Where
- 252 sites in United States, Argentina and 26 more
- Volunteers
- 621 people
- Sponsor
- Puma Biotechnology, Inc.
Breast Cancer
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor…
- Trial name
- INAVO121 (NCT05646862)
- Testing
- Inavolisib, Fulvestrant, Alpelisib
- Where
- 210 sites in United States, Argentina and 18 more
- Volunteers
- 420 people
- Sponsor
- Hoffmann-La Roche
HER2-positive Breast Cancer, HER2-positive Carcinoma
Margetuximab Expanded Access Program
The purpose of the Expanded Access program is to provide margetuximab to patients with pretreated HER2+ breast cancer for whom potential benefit justifies potential treatment risks.
- Trial name
- NCT03133988
- Testing
- Margetuximab
- Sponsor
- TerSera Therapeutics LLC
Neoplasms, Breast
Brain Metastases In ErbB2-Positive Breast Cancer
This study is for patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain radiotherapy) or SRS (stereotactic…
- Trial name
- NCT00437073
- Testing
- capecitabine, topotecan, lapatinib
- Where
- 44 sites in United States, Austria and 9 more
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
A study to assess the efficacy and safety of Dato-DXd in the pre-chemotherapy setting for patients with metastatic HR-positive, HER2 IHC 0 breast cancer.
- Trial name
- TB06 (NCT07205822)
- Testing
- Dato-DXd
- Where
- 40 sites in United States, China and 4 more
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Locally Advanced or Metastatic Breast Cancer
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
GB491-004 is a multicenter, randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of GB491 in combination with fulvestrant in patients with HR-positive, HER2-negative locally advanced or…
- Trial name
- NCT05054751
- Testing
- GB491+ Fulvestrant
- Where
- 54 sites in China
- Volunteers
- 275 people
- Sponsor
- Genor Biopharma Co., Ltd.
Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer.
- Conditions
- Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer
- Trial name
- NCT07510802
- Testing
- Dual-target CAR-NK cells, Lymphodepleting, Supportive care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Oestrogen Receptor Positive Advanced Breast Cancer
An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis
Determine the overall response rate (ORR) at 48 weeks to everolimus (RAD001, 10mg daily p.o.) and exemestane (25mg daily p.o.) treatment in postmenopausal women with oestrogen receptor positive breast cancer who have previous…
- Trial name
- 4EVERUK (NCT01743560)
- Testing
- RAD001, Exemestane
- Where
- 11 sites in United Kingdom
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer Metastatic
A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations
This research study is evaluating the efficacy and safety of TSL-1502 capsules in patients with breast cancer, will be included HER2-negative locally advanced or metastatic breast cancer patients with germline BRCA mutations.
- Trial name
- NCT05420779
- Testing
- TSL-1502 capsules(low dose), TSL-1502 capsules(high dose), Investigator's choice of chemotherapy
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
Breast Neoplasms, Breast Diseases
Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
The purpose of this study is to determine whether BNP7787 is effective in preventing or reducing neurotoxicity (nerve damage) caused by paclitaxel (Taxol®).
- Conditions
- Breast Neoplasms, Breast Diseases, Metastases, Neoplasm
- Trial name
- NCT00039780
- Testing
- BNP7787
- Volunteers
- 764 people
- Sponsor
- BioNumerik Pharmaceuticals, Inc.
Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
This phase I trial studies the side effects and best dose of alpha-TEA when given together with trastuzumab and to see how well they work for the treatment of HER2+ breast cancer that does not respond to treatment (refractory)…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma, Refractory Breast Carcinoma
- Trial name
- NCT04120246
- Testing
- Alpha-tocopheryloxyacetic Acid, Trastuzumab
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Veana Therapeutics
Breast Cancer
Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel is more effective than docetaxel for breast cancer.
- Trial name
- NCT00002662
- Testing
- docetaxel, paclitaxel
- Where
- 32 sites in United States
- Sponsor
- Aventis Pharmaceuticals
Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-)
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer.
- Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
- Trial name
- NCT07318805
- Testing
- PF-08032562, Fulvestrant, Cetuximab
- Where
- 13 sites in United States
- Volunteers
- 260 people
- Sponsor
- Pfizer
Metastatic Breast Cancer
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
This was a multi-institutional, open-label, single-arm, Phase II study of trastuzumab emtansine (T-DM1) administered by intravenous (IV) infusion to patients with human epidermal growth factor receptor 2 (HER2)-positive…
- Trial name
- NCT00509769
- Testing
- Trastuzumab emtansine [Kadcyla]
- Where
- 40 sites in United States
- Volunteers
- 112 people
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.